FDA Grants AP Status for Levetiracetam Supplement by Strides Pharma
The FDA has granted Abbreviated Approval (AP) status for a supplement application of levetiracetam submitted by Strides Pharma.
Asset / Drug
Drug and asset intelligence for Levetiracetam with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has approved a supplemental application for levetiracetam submitted by Chartwell RX.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.